Bull and Bear

Bull and Bear

Verdict: Watchlist — the negative-enterprise-value math is genuinely rare, but the Q1 2026 print ($26.7M revenue, $151M operating loss) just broke the inflection narrative the entire 2H 2025 rally was priced on, and the buyback authorized in August 2025 sits ~1% executed eight months later — meaning the people closest to the cash arb aren't acting like it exists. The decisive tension is not whether Daqo is the lowest-cost survivor (it is) but whether the Beijing-mandated price floor binds in volume as well as price. Bull's math works only if H1 2026 confirms Q1 was a deliberate production cut; Bear's math works if Q1 was the floor failing. That observation arrives within two quarters, and waiting for it costs little when the optionality this deep below cash should still be available if the recovery is real. A second sub-$100M revenue quarter, a fresh PP&E impairment, or evidence of capital trapped at the Xinjiang Daqo sub would resolve the debate against ownership; an SPV-driven nameplate retirement plus a print back above $200M would resolve it in favor.

Bull Case

Price target: $42 over a 12–18 month timeline, derived from reversion to the 7-year median P/B of 0.63× applied to FY25 book value per share of $65.43 (implied $41.22). The primary catalyst is the first SPV-driven retirement — not idling — of Chinese polysilicon nameplate capacity in H2 2026, the event that converts the policy floor from rhetoric into observable supply discipline. Disconfirming signal: polysilicon ASP printing below Daqo's $6.61/kg full-year cash cost for two consecutive quarters in 2026, or a fresh long-lived-asset impairment in H1 2026.

Bear Case

Downside target: $11/share (~−42% from $19.03) over a 12–15 month timeline. Method: liquid-asset-only valuation starting at $1.94B cash, FY26 burn of $400M to $1.54B, 30% capital-trap discount for the Cayman parent / Xinjiang Daqo STAR-listed sub structure (UFLPA, Entity List, no dividend record, FPI), zero credit to PP&E given Phase 5B impairment risk, and a residual sub-cash discount consistent with how distressed China silicon-chain peers actually trade (JKS 0.60× book, CSIQ 0.57× book). Primary trigger: the next 6-K/10-Q confirming Q1 2026 was not a one-off — a second consecutive sub-$100M revenue quarter or a forced long-lived-asset impairment. Cover signal: Q2 2026 revenue back above $200M and the consolidation SPV announcing actual nameplate retirements (not idling).

The Real Debate

Verdict

Watchlist. Bear carries more weight on the timing — Q1 2026 is a recent, empirical, hard-to-explain print, and a ~1%-executed buyback at sub-cash is governance evidence that no policy framework can paper over. The single most important tension is whether Q1 was a deliberate production cut or the floor failing in volume, because all three of Bull's points (negative EV, low-cost curve position, survivability) are mathematically correct but worth zero if the cash buffer drains faster than book can re-rate. Bull could still be right: at $0.66 per dollar of net cash with the lowest cost stack on the curve and Beijing engineering forced consolidation, the optionality is asymmetric if even half the policy story binds — and an option this far below intrinsic does not need to be bought today to be bought right. The verdict changes to Lean Long on confirmation that H1 2026 revenue prints above $200M with at least one disclosed SPV-driven nameplate retirement; the verdict changes to Avoid on a second sub-$100M revenue quarter, a fresh long-lived-asset impairment, or any sign that cash is trapped at the Xinjiang Daqo sub. Until one of those lands, the right institutional posture is to track without committing capital.